The purpose of this study is to evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP for the treatment of the GCB subtype of DLBCL.

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.

The purpose of this study is to learn how microbes in the uterus and gut (bacteria, viruses, fungi) and your own innate immune system (the first line of defense of the body) impacts how well certain treatments work for endometrial cancer. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Researchers are trying to find out if they can slow the growth of prostate cancer by adding green tea to patients treatment. Researchers are also trying to find out if this could be better or worse than usual care patients get.

We are doing a study to see if a new treatment, called INO-3107, can help people with recurrent respiratory papillomatosis (RRP). We want to find out if this treatment works well and if it helps patients need fewer surgeries in the future.

Do you have incurable, metastatic head and neck squamous cell carcinoma ? If so, you may be able to take part in a study to see if a new drug called Cisplatin is effective.

The purpose of this study is to collect cells from your esophagus using a special tool called the EndoSign® Cell Collection Device and test them to check for a condition called Barrett's Esophagus and esophageal cancer (EAC).

In this study, we want to see if a new drug called LBS-007 can help treat or cure leukemia. We want to find out if it is safe and if it works well for people with this disease.

This research study seeks to improve the treatment of early-stage breast cancer by examining circulating tumor DNA (ctDNA). CtDNA, a biomarker found in the blood, may indicate the presence of residual disease after initial treatment. The study aims to determine if ctDNA analysis can help doctors personalize adjuvant therapies, such as radiation and systemic therapy, leading to more effective treatment plans. A significant focus is placed on including African American/Black patients, a population often underrepresented in genomic research. By analyzing ctDNA in this group, researchers hope to gain valuable insights into the disease's characteristics and improve treatment outcomes, ultimately reducing disparities in breast cancer care. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.